Iida, Yuko
Wakuda, Kazushige
Kenmotsu, Hirotsugu
Doshita, Kosei
Kodama, Hiroaki
Nishioka, Naoya
Miyawaki, Eriko
Miyawaki, Taichi
Mamesaya, Nobuaki
Kobayashi, Haruki
Omori, Shota
Ko, Ryo
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Sugino, Takashi
Gon, Yasuhiro
Takahashi, Toshiaki
Article History
Received: 18 May 2023
Accepted: 27 March 2024
First Online: 1 April 2024
Competing interests
: Dr. Wakuda reports receiving grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from AstraZeneca K.K., grants from Novartis Pharma K.K., grants from AbbVie, grants from AMGEN, grant and personal fees from MSD K.K., grant and personal fees from Daiichi Sankyo Co., Ltd., grant from Dizal Pharma, personal fees from Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly K.K, Ono Pharmaceutical, Janssen Pharmaceutical K.K., Takeda Pharmaceutical, and Nihon Kayaku, outside the submitted work. Dr. Kenmotsu reports receiving personal fees from AMGEN, grants and personal fees from AstraZeneca K.K., personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Bristol-Myers Squibb, personal fees from Chugai Pharmaceutical Co., personal fees from Daiichi-Sankyo Co., Ltd., grants and personal fees from Novartis Pharma K.K., grants from Loxo Oncology, grants and personal fees from Ono Pharmaceutical Co, Ltd., grants and personal fees from Eli Lilly K.K., personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Taiho Pharmaceuticals, personal fees from Takeda Pharmaceutical Co., Ltd, personal fees from Merck Biopharma Co., Ltd., personal fees from MSD K.K, personal fees from Pfizer, outside the submitted work. Dr. Doshita reports receiving personal fees from Eli Lilly K.K., outside the submitted work. Dr. Mamesaya reports receiving grants and personal fees from Boehringer Ingelheim, personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Taiho Pharmaceuticals, personal fees from MSD K.K., personal fees from AstraZeneca K.K., personal fees from Ono Pharmaceutical Co., Ltd., outside the submitted work. Dr. Kobayashi reports receiving personal fees from Eli Lilly K.K., personal fees from Novartis Pharma K.K., personal fees from Taiho Pharmaceutical., personal fees from AstraZeneca K.K., personal fees from Chugai Pharmaceutical Co., LTD., and personal fees from Ono Pharmaceutical Co., LTD., outside the submitted work. Dr. Omori reports receiving grants and personal fees from Daiichi-Sankyo Co., Ltd., personal fees from Chugai Pharmaceutical Co., personal fees from AstraZeneca K.K., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Novartis Pharma K.K., personal fees from Taiho Pharmaceuticals, personal fees from Eli Lilly Japan K.K., personal fees from Daiichi Sankyo Co., Ltd., personal fees from Amgen K.K., outside the submitted work. Dr. Ko reports receiving grants and personal fees from Boehringer Ingelheim, grants from MSD K.K., personal fees from Taiho Pharmaceuticals, personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Eli Lilly K.K., personal fees from Boehringer Ingelheim, personal fees from Pfizer Inc., and personal fees from AstraZeneca K.K., outside the submitted work. Dr. Ono reports receiving personal fees from AstraZeneca K.K., personal fees from Chugai Pharmaceutical Co., Ltd., and personal fees from Ono Pharmaceutical Co., Ltd., outside the submitted work. Dr. Naito reports receiving grants from Otsuka Pharmaceutical K.K., personal fees from Ono Pharmaceutical Co., Ltd., and personal fees from Helsinn Healthcare SA, outside the submitted work. Dr. Murakami reports receiving grants and personal fees from AstraZeneca K.K., grants and personal fees from Takeda Pharmaceutical Co., Ltd., grants from Daiichi-Sankyo Co., grants and personal fees from AbbVie, grants from IQvia, grants and personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Bristol-Myers Squibb Japan, personal fees from MSD K.K., personal fees from Pfizer Inc., personal fees from Novartis Pharma K.K., personal fees from Eli Lilly Japan K.K., and personal fees from Taiho Pharmaceuticals, personal fees from Boehringer Ingelheim, personal fees from Eisai, personal fees from Nihon Kayaku, outside the submitted work. Dr. Takahashi reports receiving grants and personal fees from AstraZeneca K.K., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Eli Lilly Japan K.K., grants and personal fees from Ono Pharmaceutical Co., Ltd., grants and personal fees from MSD, grants and personal fees from Pfizer Japan Inc., grants and personal fees from Boehringer Ingelheim Japan, grants from Merck Biopharma Co., Ltd., grants from Amgen Inc., personal fees from Roche Diagnostics K.K., personal fees from Takeda Pharmaceuticals Co., Ltd., and personal fees from Yakult Honsha Co. Ltd., outside the submitted work. The remaining authors have nothing to disclose.